Work

Comparing 5-year and 10-year predicted cardiovascular disease risks in Aotearoa New Zealand: national data linkage study of 1.7 million adults

Year: 2024

Type: article

Abstract: AIMS: There is no consensus on the optimal time horizon for predicting cardiovascular disease (CVD) risk to inform treatment decisions. New Zealand and Australia recommend 5 years, whereas most countries recommend 10 years. We compared predicted risk and treatment-eligible groups using 5-year and 10-year equations. METHODS AND RESULTS: Individual-level linked administrative data sets identified 1 746 665 New Zealanders without CVD, aged 30-74 years in 2006, with follow-up to 2018. Participants were randomly allocated to derivation and validation cohorts. Sex-specific 5-year and 10-year risk prediction models were developed in the derivation cohort and applied in the validation cohort. There were 28 116 (3.2%) and 62 027 (7.1%) first CVD events that occurred during 5-year and 10-year follow-ups, respectively (cumulative risk, derivation cohort). Median predicted 10-year CVD risk (3.8%) was approximately 2.5 times 5-year risk (1.6%), and 95% of individuals in the top quintile of 5-year risk were also in the top quintile of 10-year risk, across age/gender groups (validation cohort). Using common guideline-recommended treatment thresholds (5% 5-year and 10% 10-year risk), approximately 14% and 28% of women and men, respectively, were identified as treatment-eligible applying 5-year equations compared with 17% and 32% of women and men applying 10-year equations. Older age was the major contributor to treatment eligibility in both sexes. CONCLUSION: Predicted 10-year CVD risk was approximately 2.5 times 5-year risk. Both equations identified mostly the same individuals in the highest risk quintile. Conversely, commonly used treatment thresholds identified more treatment-eligible individuals using 10-year equations, and both equations identified approximately twice as many treatment-eligible men as women. The treatment threshold, rather than the risk horizon, is the main determinant of treatment eligibility.

Source: European Journal of Preventive Cardiology

DOI: 10.1093/eurjpc/zwae361